Clinical implications of migraine in systemic lupus erythematosus: Relation to cumulative organ damage

Cephalalgia

Volumn 24, Issue 12, 2004, Pages 1024-1030

  Appenzeller, Simone ^a   Costallat, L T L ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Antiphospholipid antibodies; Cumulative organ damage; Migraine; Systemic lupus erythematosus

Indexed keywords

PHOSPHOLIPID ANTIBODY;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; ARTICLE; CHI SQUARE DISTRIBUTION; CONTROLLED STUDY; DISEASE ACTIVITY; FEMALE; FISHER EXACT TEST; HUMAN; MAJOR CLINICAL STUDY; MALE; MIGRAINE; RAYNAUD PHENOMENON; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADOLESCENT; ADULT; ANTIBODIES, ANTIPHOSPHOLIPID; ARTHRITIS, RHEUMATOID; COMORBIDITY; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; MIGRAINE DISORDERS; RAYNAUD DISEASE;

EID: 9644275482     PISSN: 03331024     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-2982.2004.00785.x     Document Type: Article

References (42)

1. Omdal R, Mellgren SI, Husby G. Clinical neuropsychiatric and neuromuscular manifestations in systemic lupus erythematosus. Scand J Rheumatol 1988, 17:113-7.
2. Feinglass EJ, Arnett FC, Dorsch CA, Zizic TM, Stevens MB. Neuropsychiatric manifestations of systemic lupus erythematosus: diagnosis, clinical spectrum and relationship to other features of the disease. Medicine 1976; 55:323-39.
3. Adelman DC, Saltiel E, Klinenberg JR. The neuropsychiatric manifestations of systemic lupus erythematosus: An overview. Semin Arthritis Rheum 1986; 15:185-99.
4. Johnson RT, Richardson EP. The neurological manifestations of systemic lupus erythematosus. Medicine 1968; 47:337-69.
5. Fernandez-Nebro A, Palacios-Munoz R, Gordillo J, Abarca-Costalgo M, De Haro-Liger M, Rodriguez-Andreu J et al. Chronic or recurrent headache in patients with systemic lupus erythematosus: a case control study. Lupus 1999; 8:151-6.
6. Vazquez-Cruz J, Traboulssi H, Rodriguez-De la Serna A, Geli C, Roig C, Diaz C. A prospective study of chronic or recurrent headache in systemic lupus erythematosus. Headache 1990; 30:232-5.
7. Glanz BI, Venkatesan A, Schur PH, Lew RA, Khoshbin S. Prevalence of migraine in patients with systemic lupus erythematosus. Headache 2001; 41:285-9.
8. Sfikakis PP, Mitsikostas DD, Manoussakis MN, Foukaneli D, Moutsopoulos HM. Headache in systemic lupus erythematosus: a controlled Study. Br J Rheumatol 1998; 37:300-3.
9. Omdal R, Waterloo K, Koldingsnes W, Husby G, Mellgren SI. Somatic and psychological features of headache in systemic lupus erythematosus. J Rheumatol 2001; 28:772-9.
10. Ainiala H, Loukkola J, Peltola J, Korpela M, Hietaharju A. The prevalence of neuropsychiatric syndromes in systemic lupus erythematosus. Neurology 2001; 57:496-500.
11. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25:1271-7.
12. The American College of Rheumatology Nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 1999; 42:599-608.
13. Arnett FC. Revised criteria for the classification of rheumatoid arthritis. Bull Rheum Dis 1989; 38:1-6.
14. Harris EN, Gharavi AE, Patel SP, Hughes GR. Evaluation of the anticardiolipine antibody test: report of an international workshop held 4 April 1986. Clin Exp Immunol 1987; 68:215-22.
15. Brandt JT, Triplett DA, Alving B, Scharer I. Criteria for the diagnosis of lupus anticoagulant: an update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Thromb Haemost 1995; 74:1185-90.
16. Guzman J, Cardiel MH, Arce-Salinas A, Sanchez-Guerrero J, Alarcon-Segovia D. Measurement of disease activity in SLE. Prospective validation of 3 clinical indices. J Rheumatol 1992; 19:1551-8.
17. Gladman DD, Urowitz MB, Kagal A, Hallett D. Accurately describing changes in disease activity in systemic lupus erythematosus. J Rheumatol 2000; 27:377-9.
18. Gladman DD, Urowitz MB, Goldsmith CH, Fortin P, Ginzler E, Gordon C et al. The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. Arthritis Rheum 1997; 40:809-13.
19. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988; 8 Suppl 7:1-96.
20. Solomon S. Diagnosis of primary headache disorders. Validity of the International Headache Society criteria in clinical practice. Neurol Clin 1997; 15:15-26.
21. Pajaron E, Lainez JM, Monzon MJ, Parra J, Peiro C, Sancho J. The validity of the classification criteria of the International Headache Society for migraine, tension headache and chronic tension headache. Neurologia 1999; 14:283-8.
22. Bensenor IJ, Lotufo PA, Pereira AC, Tannuri AC, Issa FK, Akashi D et al. Validation of a questionnaire for the diagnosis of headache in an outpatient clinic at a University hospital. Arq Neuropsiquiatr 1997; 55:364-9.
23. Weitzel KW, Strickland JM, Smith KM, Goode JV. Gender-specific issues in the treatment of migraine. J Gend Specif Med 2001; 4:64-74.
24. Isenberg DA, Meyrick-Thomas D, Snaith ML, McKeran RO, Royston JP. A study of migraine in systemic lupus erythematosus. Ann Rheum Dis 1982; 41:30-2.
25. Markus HS, Hopkinson N. Migraine and headache in systemic lupus erythematosus and their relationship with antibodies against phospholipids. J Neurol 1992; 239:39-42.
26. Silman A, Holligan S, Brennan P, Maddison P. Prevalence of symptoms of Raynaud's phenomenon in general practice. Br Med J 1990; 301:590-2.
27. Heslop J, Coggon D, Acheson ED. The prevalence of intermittent digital ischaemia in a general practice. J Roy Coll General Pract 1983; 33:85-9.
28. O'Keeffe ST, Tsapatsaris NP, Beetham WP Jr. Association between Raynaud's phenomenon and migraine in a random population of hospital employees. J Rheumatol 1993; 20:1187-8.
29. Spierings EL. Pathogenesis of the migraine attack. Clin J Pain 2003; 19:255-62.
30. Hanly JG. Antiphospholipid syndrome: an overview. CMAJ 2003; 168:1675-82.
31. Bombeli T, Karsan A, Tait JF, Harlan JM. Apoptotic vascular endothelial cells become procoagulant. Blood 1997; 89:2429-42.
32. Ma K, Simantov R, Zhang JC, Silverstein R, Hajjar KA, McCrae KR. High affinity binding of beta 2-glycoprotein I to human endothelial cells is mediated by annexin II. J Biol Chem 2000; 275:15541-8.
33. Del Papa N, Moroni PL, Tincani A, Harris EN, Pierangeli SS, Barcellini W et al. Relationship between antiphospholipid and anti-endothelial cell antibodies: further characterization of the reactivity on resting and cytokine-activated endothelial cells. Clin Exp Rheumatol 1992; 10:37-42.
34. Simantov R, LaSala JM, Lo SK, Gharavi AE, Sammaritano LR, Salmon JE et al. Activation of cultured vascular endothelial cells by antiphospholipid antibodies. J Clin Invest 1995; 96:2211-9.
35. Del Papa N, Guidali L, Sala A, Buccellati C, Khamashta MA, Ishikawa K et al. Endothelial cells as target for antiphospholipid antibodies. Human polyclonal and monoclonal anti-beta 2-glycoprotein I antibodies react in vitro with endothelial cells through adherent beta 2-glycoprotein I and induce endothelial activation. Arthritis Rheum 1997; 40:551-61.
36. Hanly JG, Hong C, Issekutz A. Beta 2-glycoprotein I and anticardiolipin antibody binding to resting and activated cultured human endothelial cells. J Rheumatol 1996; 23:1543-9.
37. Montalban J, Cervera R, Font J, Ordi J, Vianna J, Haga HT et al. Lack of association between anticardiolipin antibodies and migraine in systemic lupus erythematosus. Neurology 1992; 3:681-2.
38. Uziel Y. Headache in SLE. Clin Exp Rheumatol 2000; 18 (3):421.
39. Aarli JA. Immunological aspects of epilepsy. Brain Dev 1993; 15:41-9.
40. Herranz MT, Rivier G, Khamashta MA, Blaser KU, Hughes GR. Association between antiphospholipid antibodies and epilepsy in patients with systemic lupus erythematosus. Arthritis Rheum 1994; 37:568-71.
41. Whitlaw DA, Spangenberg JJ, Rickman R, Hugo FH, Roberts M. An association between the Antiphospholipid Antibody and neurological Impairment in SLE. Lupus 1999; 8:444-8.
42. Shrivastava A, Dwivedi S, Aggarwal A, Misra R. Anticardiolipin and anti-beta2 glycoprotein I antibodies in Indian patients with systemic lupus erythematosus. association with the presence of seizures. Lupus 2001; 10:45-50.